International Hepatology

Professor Jerome Boursier played a leading role in a multi-center study evaluating non-invasive tests (NITs) for fibrotic MASH, published in JHEP Reports. This study addresses a critical challenge in MASH…

A multi-center study across 13 centers in five countries evaluated the long-term outcomes of CARTO/PARTO for gastric variceal (GV) bleeding in 311 patients over 10 years.The results show excellent survival…

In January 2025, Scientific Reports published an observational pilot study evaluating the long-term efficacy and safety of entecavir (ETV) versus tenofovir alafenamide (TAF) in patients with chronic hepatitis B.Key Findings:After…

In January 2025, Clinical Gastroenterology and Hepatology published a narrative review titled "Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma."With MASLD (Metabolic Dysfunction-associated Steatotic…

In January 2025, the Journal of Hepatology published a thought-provoking letter titled "Beyond Portal Hypertension: Characterizing Porto-Sinusoidal Vascular Disorder in Patients without Signs of PH." This study sheds new light…

In January 2025, the Journal of Clinical Oncology published an important Grand Rounds article titled "Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers."This piece delves into…

Introduction: Hepatocellular carcinoma (HCC) is a major global health burden, ranking as the third leading cause of cancer-related deaths worldwide. Despite liver resection being a curative option in the Asia-Pacific…

Editor's Note: A recent study titled “Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040” by Dr. Fanpu Ji’s team from the Second Affiliated Hospital of…

During the recently concluded 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), we had the privilege of conducting an in-depth interview with Dr. Jiangao…

Editor's Note: In the field of viral hepatitis, while most chronic hepatitis B (CHB) patients receiving tenofovir alafenamide (TMF) antiviral therapy experience a rapid decline in HBV DNA levels, only…